AstraZeneca's R&D strategy not big on innovation
A series of recent high-profile drug failures has AstraZeneca's chief executive David Brennan in search of new drugs for his pipeline. The London Times states, As well as being costly, the failures have left the group dangerously exposed, with just a few products left in its late-stage pipeline